CONTACT US   |  (864) 397-5101

Charleston-based MUSC partners with startup to develop AI platform

MUSC logo

The Medical University of South Carolina health system and Quai.MD, a deep-tech startup offering an artificial intelligence (AI)-based clinical pathways platform, entered into a strategic licensing agreement to advance their unique platform.

This agreement will impact physician productivity, patient outcomes and hospital billing efficiency by highlighting and tracking possible clinical pathways and the diagnostic decisions of patients, an MUSC Health news release stated. Clinical pathways are tools that guide evidence-based health care, translating clinical practice guideline recommendations into clinical processes of care in an effort to deliver the optimal individualized patient care possible.

Clinical pathways and protocols, as they exist today across health care, can lead to variability in the hospital setting as they are not always specific to each patient undergoing care, the release stated. Quai.MD will support physicians in their workflow patterns and synthesize the protocols and pathways that MUSC Health leadership will define, the results of which will improve physician documentation and ensure billing efficiencies.

“Clinical pathways are ubiquitous in theory but are only partially utilized in practice. Physicians feel empowered by our platform because our AI-engine tailors the pathway to the specific patient while allowing physicians full flexibility to choose whatever path they see fit,” said Dr. Chen Shapira, chief medical officer with Quai.MD, in the release. “Quai.MD helps providers take the right path to reach a decision quickly and precisely while reducing care variability.”

MUSC will begin implementation of the AI solution in 2023.

“Running a health care system requires maintaining a constant balance of cost control and optimal care quality,” said Lisa Goodlett, CPA, chief financial officer at MUSC Health. “Adhering to clinical pathways helps to reduce cost while increasing the quality of care. Quai.MD can help us take those pathways developed in our academic facility and proliferate them throughout the system – to raise the overall standard of care while increasing efficiency and revenue.”

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.